Dane Osmond

Associate Director
BioMarin Pharmaceuticals Inc.
Novato, California, United States

Presentation(s):

• OC 30.1 - Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A

  Monday, June 24, 2024
  09:30 – 09:45 ICT